Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients.
Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I · 2009 · Diabetes care
What does this source report?
Neuropathic symptoms improved versus placebo. The vibration-threshold coprimary analysis over time did not reach statistical significance, although the final-visit comparison did.
- Population and setting
- 567 treated participants with type 2 diabetes and symptomatic polyneuropathy
- Evidence type
- Randomized trial
- Preparation
- Deproteinized calf-blood derivative
- Source language
- English
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Endpoint timing matters; these findings do not establish general nerve regeneration or benefit in healthy people. No difference in adverse-event incidence was reported during this trial.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Indexed citation and abstract checked; full methods and risk-of-bias appraisal remain incomplete.
Recorded source-check date: 2026-09-30. This date does not imply a completed systematic review.
Source provenance: Journal publication
Open original source or index record ↗
DOI: 10.2337/dc09-0545
Cite and trace this record
Original source: Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes care 2009.
Molekul research summary: https://molekul.io/research/actv-19470838. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry